Diclofenac Topical

Introduction Overview

Generic Name

diclofenac topical

Brand Name

Voltaren Arthritis Pain Gel

Dosage Form

Topical gel

Drug Class

Topical non-steroidal anti-inflammatories (NSAIDs)

Pharmacokinetics

Absorption:
Diclofenac topical gel is absorbed transdermally through the skin at the site of application, leading to localized tissue concentrations with minimal systemic exposure. The absorption rate may vary depending on the skin condition, integrity, and thickness, as well as environmental factors such as temperature. When applied to intact skin, diclofenac penetrates the epidermis and dermis, concentrating in underlying tissues, particularly in the synovial fluid and tissues of joints affected by osteoarthritis. Systemic absorption is considerably less than that observed with oral administration, thereby reducing systemic adverse effects. Factors such as use of heat or occlusive dressings can significantly increase the absorption, potentially leading to higher systemic exposure. Clinical studies have demonstrated that the plasma concentrations of diclofenac following topical administration are approximately 5- to 17-fold lower compared to equivalent oral doses.

Distribution:
Once absorbed, diclofenac topical gel exhibits preferential distribution to the site of pain and inflammation, particularly in joint tissues such as the synovium, cartilage, and periarticular tissues. Due to its topical application, systemic distribution is limited, resulting in lower plasma concentrations. Diclofenac is highly protein-bound (>99%) when systemically absorbed, primarily to albumin. This high protein binding limits its free active concentration in circulation but facilitates delivery to sites of inflammation. The distribution volume after topical application is minimal and localized, which contributes to its targeted therapeutic effect with fewer systemic effects. Tissue concentrations after topical use may approach those seen with oral therapy within treated joints, providing localized anti-inflammatory benefits.

Metabolism:
Diclofenac undergoes extensive hepatic metabolism primarily via cytochrome P450 enzymes, notably CYP2C9, leading to hydroxylated metabolites that are subsequently conjugated before excretion. Metabolic pathways include oxidation to 4'-hydroxydiclofenac and 5-hydroxydiclofenac followed by glucuronidation and sulfation. Because systemic absorption from topical use is low, overall metabolic burden is significantly decreased compared to oral administration. However, any systemically absorbed diclofenac is rapidly metabolized in the liver with a high first-pass effect that further limits systemic circulation of active drug. The topical formulation bypasses gastrointestinal metabolism while still undergoing hepatic metabolism once absorbed.

Elimination:
Diclofenac and its metabolites are predominantly eliminated through renal excretion, with a smaller fraction excreted in the bile. Approximately 65-70% of an administered dose is excreted in urine mainly as metabolites, and the remainder is eliminated via feces. The elimination half-life of diclofenac after topical administration is about 1-2 hours, similar to systemic administration, reflecting rapid clearance. Due to low systemic exposure, accumulation is unlikely with topical use when dosing guidelines are followed. Renal function impairment can affect elimination of metabolites and should be considered clinically, particularly in elderly patients or those with compromised renal function. Overall, topical diclofenac offers effective local treatment with limited systemic exposure and elimination akin to oral formulations but with a better safety profile.

Dosage Forms

Available Dosage Forms:
Voltaren Arthritis Pain Gel is supplied as a 1% diclofenac sodium topical gel. It is formulated as a clear, colorless to pale yellow gel intended for local application to painful joints affected by osteoarthritis. The gel is available in tubes of various sizes for patient convenience.

Dosages for Adults and Adolescents:
For osteoarthritis pain relief, dosing is stratified based on the joint involved:
- Lower Extremities (ankle, knee, foot): Apply 4 grams of gel to the entire affected area 4 times daily, not exceeding 16 grams per single joint per day.
- Upper Extremities (hand, wrist, elbow): Apply 2 grams of gel to the entire affected area 4 times daily, not exceeding 8 grams per single joint per day.
- Maximum total dose across all treated joints should not exceed 32 grams per day.
Application instructions emphasize even and gentle rubbing of the gel into the skin, covering the entire affected area (e.g., whole foot or hand including toes or fingers) using dosing cards provided. Patients are advised to avoid treating multiple or large joints simultaneously beyond recommended limits.

Specific Patient Populations:
Special considerations are advised in elderly patients who may be at increased risk for adverse events related to NSAID use. Usage in pregnancy is generally avoided, particularly beyond 20 weeks gestation due to risk to fetal cardiovascular and renal development. Safety during breastfeeding is not established and should be discussed with a healthcare provider. Patients with hepatic or renal impairment should use with caution due to the potential for altered systemic drug clearance even though systemic absorption is low. Application should be avoided on damaged or broken skin, burns, or infected areas. Heat exposure (e.g., heating pads, hot tubs) is contraindicated as it can increase systemic absorption, potentially raising the risk of systemic adverse effects.

Clinical guidelines recommend adherence to dosing cards supplied, washing hands after application (unless treating the hands), and waiting at least one hour before bathing or showering to prevent removal of the medication.

Mechanism Of Action

Voltaren Arthritis Pain Gel contains diclofenac, a nonsteroidal anti-inflammatory drug (NSAID) that exerts its therapeutic effects by inhibiting cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. These enzymes are critical in the biosynthesis of prostaglandins, lipid compounds that mediate inflammation, pain, and fever. By blocking COX activity, diclofenac decreases the production of prostaglandins at sites of tissue injury and inflammation, thereby reducing the pain and swelling associated with osteoarthritis.

After topical application, diclofenac penetrates the skin and accumulates in underlying structures such as the synovium, cartilage, and periarticular tissues of affected joints. This allows localized suppression of prostaglandin synthesis directly within the inflamed joint, which contributes to its analgesic and anti-inflammatory effects with minimal systemic drug exposure. The reduction in prostaglandins also decreases vasodilation and vascular permeability, attenuating edema and inflammatory cell infiltration.

Diclofenac’s inhibition of COX enzymes is reversible and competitively inhibits the active site, disrupting the conversion of arachidonic acid to prostaglandin H2, the precursor of other prostaglandins and thromboxanes. Topical administration bypasses first-pass hepatic metabolism seen with oral NSAIDs, reducing the risk of gastrointestinal adverse effects while maintaining efficacy locally.

Comparatively, diclofenac demonstrates slightly higher selectivity for COX-2 compared to some other NSAIDs, which may contribute to a more favorable balance of anti-inflammatory effect and gastrointestinal tolerability. Clinical studies support its effectiveness in reducing osteoarthritis pain in joints accessible to topical therapy, such as the hands and knees. Importantly, since the gel formulation limits systemic absorption, the risk of systemic effects like cardiovascular events, though present, is lower than with oral NSAIDs but still warrants caution for prolonged use or in susceptible patients.

Pharmacological Actions

Inhibition of cyclooxygenase (COX-1 and COX-2) enzymes, leading to decreased prostaglandin synthesis.
Reduction of inflammation by suppressing inflammatory mediators in joint tissues.
Analgesic action through inhibition of pain mediators localized in inflamed joints.
Anti-pyretic effects, though clinically minimal with topical application.
Local accumulation in synovial fluid and periarticular tissues providing targeted therapy.
Minimal systemic absorption reduces risks of gastrointestinal, renal, and hepatic adverse effects compared to oral NSAIDs.
Reversible competitive inhibition of COX enzymes.
Suppression of vasodilation and vascular permeability reducing edema.
Reduction of inflammatory cell migration into affected tissues.
Potential impact on ovulation indicative of systemic hormonal effects at high doses or prolonged use.
Partial selectivity for COX-2 providing a relatively improved gastrointestinal tolerability profile.
Possible mild antihypertensive antagonism due to interference with renal prostaglandins.
Clinical effectiveness primarily for osteoarthritis-related pain and inflammation in joints accessible by topical administration.

Therapeutic Or Clinical Uses

Topical treatment of pain due to osteoarthritis in joints amenable to topical application such as knees, hands, wrists, elbows, ankles, and feet.
Reduction of inflammation and joint swelling associated with osteoarthritis.
Management of mild to moderate osteoarthritis pain needing localized therapy.
Alternative or adjunct to systemic NSAIDs for patients at risk for systemic NSAID adverse effects.
Useful in patients requiring NSAID therapy but with contraindications or intolerance to oral NSAIDs.
Relief of joint pain without significant systemic side effects, particularly gastrointestinal and renal.
Palliative treatment in elderly patients with localized osteoarthritis pain.
Non-opioid option for managing chronic musculoskeletal pain due to osteoarthritis.
Topical analgesic to improve function and quality of life in patients with osteoarthritis.
Suitable for repeated daily use up to the recommended maximum dose for sustained symptomatic relief.

Side Or Adverse Effects

Local skin reactions including redness, itching, dryness, scaling, or peeling at the site of application.
Occasional increased sweating in treated areas.
Systemic adverse effects are rare but can include gastrointestinal symptoms such as heartburn, nausea, vomiting, diarrhea, or constipation.
Headache, dizziness, and drowsiness reported infrequently.
Rare cases of severe allergic reactions including hives, facial swelling, and wheezing.
Potential for serious skin reactions such as rash with blistering and peeling.
Possible elevation of blood pressure.
Signs of liver impairment such as nausea, upper right abdominal pain, jaundice, and fatigue.
Anemia symptoms like pale skin, unusual tiredness, and feeling light-headed may occur.
Risk of stomach or intestinal bleeding manifested by bloody or tarry stools or vomiting with blood.
Rapid weight gain and swelling due to fluid retention.
Severe headache, blurred vision, and pounding sensation in neck or ears.
Symptoms of heart attack and stroke such as chest pain, numbness, or speech difficulties require immediate medical attention.
Rare interactions leading to increased bruising or bleeding tendency.
Photosensitivity or skin irritation exacerbated by sunlight or heat exposure.

Precautions

Avoid use if allergic to diclofenac, aspirin, or other NSAIDs due to risk of severe allergic reactions including asthma exacerbations.
Use with caution in patients with a history of heart disease, high blood pressure, or stroke due to increased cardiovascular risks.
Patients with history of stomach ulcers or gastrointestinal bleeding should use with caution due to bleeding risk.
Avoid application on broken, infected, or eczematous skin.
Do not apply heat or occlusive dressings over treated area as this can increase systemic absorption.
Pregnant women, especially beyond 20 weeks gestation, should avoid use due to risks to fetal cardiovascular and renal development.
Caution required for patients with liver or kidney impairment.
May impair female fertility by affecting ovulation; advise patients planning conception accordingly.
Avoid concomitant use of other topical skin products on the treated area to prevent irritation or interaction.
Avoid exposing treated skin to sunlight, tanning beds, or other sources of ultraviolet light.
Monitor for signs of bleeding or bruising, especially with concurrent anticoagulant or antiplatelet therapy.
Patients should avoid alcohol consumption as it may increase bleeding risks.
Use cautiously in elderly patients who are more susceptible to adverse effects.
Check for drug interactions before use, particularly with SSRIs, warfarin, lithium, methotrexate, and immunosuppressants.
Pregnancy and breastfeeding status should be evaluated prior to initiation.

Warnings

Do not use if prior severe allergic reaction or asthma attack related to aspirin or NSAIDs.
Diclofenac topical gel may increase risk of fatal heart attack or stroke, particularly with long-term use or in patients with existing heart disease.
Should not be used immediately before or after coronary artery bypass graft surgery.
Potential for fatal gastrointestinal bleeding, ulceration, and perforation which can occur without warning.
Discontinue use and seek prompt medical attention if signs of serious skin reactions occur.
Stop use immediately and contact emergency services if symptoms of heart attack or stroke appear.
Avoid use in late pregnancy due to risk of fetal harm.
Monitor for liver toxicity symptoms and discontinue if they develop.
Avoid concurrent use of systemic NSAIDs or aspirin to reduce risk of additive adverse effects.
Use caution in patients taking anticoagulants or medications that affect bleeding.
Avoid use on open wounds, infected skin, or mucous membranes.
Heat exposure over treated area increases systemic absorption, raising risk of side effects.
Not evaluated or recommended for treatment of osteoarthritis in joints not accessible to topical application such as hips or spine.
Monitor blood pressure during treatment as NSAIDs may cause hypertension.
Inform patients about potential signs of adverse reactions requiring urgent evaluation.

Contraindication

Known hypersensitivity to diclofenac, aspirin, or other NSAIDs.
History of asthma, urticaria, or allergic-type reactions after NSAID or aspirin use.
Active gastrointestinal bleeding or history of recurrent peptic ulcer disease with bleeding.
Use immediately before or after coronary artery bypass graft (CABG) surgery.
Third trimester of pregnancy due to risk of fetal harm.
Presence of open wounds, infected, or damaged skin at the application site.
Patients with severe hepatic impairment.
Severe renal impairment without close monitoring.
Patients with known bleeding disorders.
Known hypersensitivity to any component of the topical formulation.
Concomitant use with other topical NSAIDs.
Use in pediatric patients as safety and efficacy have not been established.
Patients with history of serious allergic reactions to sulfonamides, due to potential cross-reactivity.
Severe heart failure or uncontrolled hypertension.

Drug Interactions

Concomitant use with oral or systemic NSAIDs or aspirin may increase risk of adverse effects including gastrointestinal bleeding.
Increased bleeding risk when used with anticoagulants such as warfarin, Coumadin, or Jantoven.
Potential increased lithium toxicity due to decreased renal clearance when combined with diclofenac.
Enhanced risk of methotrexate toxicity due to competition for renal excretion.
Concomitant use with cyclosporine may increase nephrotoxicity risk.
Use with SSRIs (e.g., citalopram, escitalopram, fluoxetine, paroxetine, sertraline, trazodone) can increase risk of bleeding or bruising.
Diuretics and antihypertensive agents may have reduced efficacy when taken with diclofenac due to sodium and water retention.
Use with corticosteroids such as prednisone increases risk of gastrointestinal ulceration or bleeding.
May interfere with the antiplatelet effect of low-dose aspirin.
Concomitant use with other nephrotoxic drugs increases risk of renal impairment.
Avoid use with certain herbal products or supplements that affect bleeding, such as ginkgo biloba, garlic, or ginger.
Coadministration with fluvoxamine may raise plasma diclofenac levels, increasing side effect risk.
Delayed clearance of digoxin and other drugs cleared renally may occur.
Potential interactions with vitamin K antagonists requiring closer monitoring.
Other topical medications applied to the same area may alter absorption or cause irritation.

Preparations Of The Drug

Voltaren Arthritis Pain Gel 1% diclofenac sodium topical gel formulation.
Supplied in multi-use tubes with dosing cards illustrating 2-gram and 4-gram doses for precise application.
Clear, colorless to pale yellow gel base designed for easy spread and rapid absorption.
Packaged to maintain stability at room temperature; avoid freezing or excessive heat.
Accompanies patient information leaflets detailing dosing instructions, precautions, and side effects.
Available in various tube sizes for patient convenience.
Non-greasy, fast-drying topical gel formulation improving patient compliance.
Formulated without fragrances or dyes to minimize skin irritation.
Not intended for use with occlusive dressings or heating pads to prevent increased systemic absorption.
Packaging includes measures to ensure accurate dosing and prevent misuse.
Prepared under standardized manufacturing practices to ensure consistent potency and safety.
Compared to other topical diclofenac formulations (e.g., patches, solution), gel offers good spreadability and coverage over affected areas.
Compatible with standard storage and disposal recommendations for topical NSAIDs.